Open AccessRole of combining neutrophil‑to‑lymphocyte ratio and pretreatment body mass index in predicting progression‑free survival in patients with non‑small cell lung cancer treated with nivolumab
Author(s) -
Radu Dragomir,
Adelina Silvana Dragomir,
Alina Gabriela Negru,
Sorin Săftescu,
D Popovici,
Michael Schenker,
Raluca Lupușoru,
Șerban Negru
Publication year - 2021
Publication title -
experimental and therapeutic medicine
Language(s) - English
Resource type - Journals
eISSN - 1792-1015
pISSN - 1792-0981
DOI - 10.3892/etm.2021.9958
Subject(s) - nivolumab , medicine , lung cancer , body mass index , progression free survival , neutrophil to lymphocyte ratio , cancer , oncology , gastroenterology , chemotherapy , lymphocyte , immunotherapy
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom